Studies have demonstrated that TEM8/ANTXR1 is enriched in triple negative breast cancer (Xu et al., 2021), prostate cancer (Li et al., 2021a), gastric cancer (Li et al., 2021b; Sun et al., 2021), pancreatic cancer (Alcalá et al., 2019), angiosarcoma (Kusaba et al., 2021), colon cancer (Ł et al., 2021), and non-small cell lung cancer (NSCLC) (Gong et al., 2021). This evidence concerns the gene ANTXR1 and prostate carcinoma.